DeepMed Research

Henrik Gregersen

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma

Phase 2

Conditions: Multiple Myeloma
Infection

Interventions: Drug: Standard myeloma treatment
Drug: Clarithromycin
Drug: Sulfamethoxazole/trimethoprim
Drug: Observation

First Posted Date: 2015-12-08

Last Posted Date: 2015-12-08

Lead Sponsor: Henrik Gregersen

Target Recruit Count: 300

Registration Number: NCT02624440

Locations: 🇩🇰
Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Department of Hematology, Rigshospitalet, Copenhagen, Denmark
🇩🇰
Department of Hematology, Esbjerg Sygehus, Esbjerg, Denmark

and more 5 locations

Clarithromycin in Multiple Myeloma Induction Therapy

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Placebo
Drug: Clarithromycin
Drug: VCD induction therapy

First Posted Date: 2015-10-12

Last Posted Date: 2016-09-20

Lead Sponsor: Henrik Gregersen

Target Recruit Count: 58

Registration Number: NCT02573935

Locations: 🇩🇰
Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Department of Hematology, Herlev Hospital, Herlev, Denmark

and more 4 locations

Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support

Phase 2

Conditions: Multiple Myeloma

Interventions: Drug: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan
Drug: Carfilzomib/dexamethasone maintenance
Drug: Observation without carfilzomib/dexamethasone maintenance

First Posted Date: 2015-10-09

Last Posted Date: 2018-08-17

Lead Sponsor: Henrik Gregersen

Target Recruit Count: 200

Registration Number: NCT02572492

Locations: 🇸🇪
Skåne University Hospital, Lund, Sweden
🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇱🇹
Vilnius University hospital "Santariskiu Clinics", Vilnius, Lithuania

and more 2 locations

Microdose Study of Melphalan, Bortezomib and Dexamethasone

Early Phase 1

Conditions: Multiple Myeloma

Interventions: Drug: Melphalan
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2014-04-10

Last Posted Date: 2015-12-08

Lead Sponsor: Henrik Gregersen

Target Recruit Count: 6

Registration Number: NCT02109861

Locations: 🇩🇰
Department of Haematology, Aalborg University Hospital, Aalborg, Denmark

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy